Press Releases Details

Cerus Awarded $489,000 Under U.S. Qualified Therapeutic Discovery Project Program

11/03/2010

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that it has been awarded two cash grants totaling approximately $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

"This funding will be helpful to support the development of our INTERCEPT Blood System for platelets and red blood cells, which both qualified to receive a grant," said Claes Glassell, Cerus' president and chief executive officer.

The QTDP was created by Congress as part of the Patient Protection and Affordable Care Act in March 2010. The program provides a tax credit or grant equal to 50% of eligible costs and expenses for the tax years 2009 and 2010. The grants are a tax benefit targeted to therapeutic discovery projects that, among other things, show a reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect or treat chronic or acute diseases and conditions, or reduce the long-term growth of health care costs in the United States.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate both established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

    Source: Cerus Corporation